Codice QR

Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe

Over the last years non-alcoholic fatty liver disease (NAFLD) has grown into the most common chronic liver disease globally, affecting 17-38% of the general population and 50-75% of patients with obesity and/or type 2 diabetes mellitus (T2DM). NAFLD encompasses a spectrum of chronic liver diseases,...

Descrizione completa

Salvato in:
Autori principali: Maria Eleni Chondrogianni, Ioannis Kyrou, Theodoros Androutsakos, Christina-Maria Flessa, Evangelos Menenakos, Kamaljit Kaur Chatha, Yekaterina Aranan, Athanasios G. Papavassiliou, Eva Kassi, Harpal S. Randeva
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2024-03-01
Serie:Frontiers in Endocrinology
Soggetti:
anti-osteoporotic drugs
non-alcoholic fatty liver disease
denosumab
romosozumab
bisphosphonates
calcitonin
Accesso online:https://www.frontiersin.org/articles/10.3389/fendo.2024.1344376/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi